Various natural STAT3 inhibitors, such as ursolic acid and the cryptotanshinone derivative KYZ3, have limited potency, unacceptable toxicity, quick metabolism, and/or poor blood brain barrier permeability, making them inappropriate for clinical application in the treatment of GBM (Jhaveri et al., 2018). Here, STAT3 is linked to glioblastoma.